Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | ALPL | P05186 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647673 | 0.83 | ALDH1A1 (0.51) | ALDH1A1ALPLTSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL16903207 | 0.82 | LMNA (0.46) | ALDH1A1TSHRUSP2SMN1; SMN2KDM4E | |
| SCHEMBL20647803 | 0.78 | CYP3A4 (0.35) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16903204 | 0.77 | CPT1A (0.50) | ALDH1A1TSHRSMN1; SMN2KDM4ELMNA | |
| SCHEMBL20647814 | 0.74 | CYP3A4 (0.33) | ALDH1A1TSHRSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL16903206 | 0.73 | CPT1A (0.50) | ALDH1A1TSHRSMN1; SMN2LMNACPT2 | |
| SCHEMBL20647772 | 0.71 | ALDH1A1 (0.43) | ALDH1A1TSHRSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20647821 | 0.71 | OPRM1 (0.31) | — | |
| SCHEMBL20647810 | 0.70 | CYP3A4 (0.41) | ALDH1A1TSHRSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20647807 | 0.69 | SMN1; SMN2 (0.48) | ALDH1A1TSHRSMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885ALPL 984/4885TSHR 3422/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885ALPL 984/4885TSHR 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.